Evidence map›Paper›PMID 42823496›Full record

ReviewArchives of toxicology2026

Therapeutic role of fucoidans against oxidative stress: recent developments, translational challenges, and future directions.

Arduino A Mangoni, Barbara C Wimmer, Joel T Kidgell, Jai Meyers

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Arduino A MangoniDiscipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Sturt Road, Bedford Park, SA, 5042, Australia. arduino.mangoni@flinders.edu.au.ORCID https://orcid.org/0000-0001-8699-1412
Barbara C WimmerMarinova Pty Ltd, 249 Kennedy Drive, Cambridge, TAS, 7170, Australia.
Joel T KidgellMarinova Pty Ltd, 249 Kennedy Drive, Cambridge, TAS, 7170, Australia.
Jai MeyersDiscipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University, Sturt Road, Bedford Park, SA, 5042, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is increasingly recognized that redox injury, one of the most extensively studied processes in disease pathophysiology, pharmacology, and toxicology, is rarely explained by an indiscriminate excess of free radicals alone, but rather by a combination of macromolecular injury, maladaptive redox signaling, ferroptosis, and dysregulated inflammation and metabolism. This paradigm shift has revealed several limitations of traditional antioxidants, including a focus on scavenging effects, poor target engagement, unfavorable or uncertain pharmacokinetics, failure to reach specific subcellular compartments, and lack of robust biomarkers of response. Concomitantly, greater attention is currently being paid to natural compounds combining antioxidant, anti-inflammatory, and metabolic effects. Fucoidans, structurally diverse, fucose-rich, sulfated polysaccharides derived mainly from brown seaweeds, are emerging as promising candidates because they target multiple pathways relevant to oxidative injury, including activation of antioxidant systems, preservation of mitochondrial function, attenuation of ferroptosis, and modulation of gut-organ axes that amplify oxidative tissue damage. This review critically appraises studies conducted over the last ten years, with particular emphasis on newly identified mechanisms, quality of fucoidan characterization, disease-model relevance, and translational potential. Current evidence supports an antioxidant effect of fucoidans, particularly in diseases affecting the liver, kidneys, intestines, central nervous system, and skin/wound healing. However, translation is constrained by heterogeneity across source species, extraction, purification, molecular weight, and analytical reporting. Standardized chemistry, robust pharmacokinetic characterization, and comprehensive assessments of biomarkers of response and organ biology are required to validate the role of fucoidans in mitigating oxidative stress.

Indexed as

Antioxidant therapyFerroptosisFucoidansMitochondrial dysfunctionNrf2Oxidative stress

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.